Durability of serologic response after lamivudine treatment of chronic hepatitis B

Hepatology

Volumn 37, Issue 4, 2003, Pages 748-755

  Dienstag, Jules L ^a   Cianciara, Janusz ^b   Karayalcin, Selim ^c   Kowdley, Kris V ^d   Willems, Bernard ^e   Plisek, Stanilav ^f   Woessner, Mary ^g   Gardner, Stephen ^g   Schiff, Eugene ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c ANKARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

^f Infekeni Klinika   (Czech Republic)

^g GLAXOSMITHKLINE   (United States)

^h UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MEMBRANE ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; BIOSAFETY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MALE; MONITORING; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037381547     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50117     Document Type: Article

References (22)

1. Niederau C, Heintges T, Lange S, Goldmann G, Niederau C, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
2. Lau DT-Y, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660-1667.
3. Fagan EA, Alexander GJ, Davison F, Williams R. Persistence of free HBV DNA in body secretions and liver despite loss of serum HBV DNA after interferon-induced seroconversion. J Med Virol 1986;20:183-188.
4. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-WL, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
5. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia lamivudine study group. N Engl J Med 1998;339:61-68.
6. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
7. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Petrillo R, Dienstag J, Husa P, Schalm S, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy [Abstract]. HEPATOLOGY 1998;28:388A.
8. Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, Gelb LD, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. HEPATOLOGY 1999;30:1082-1087.
9. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. HEPATOLOGY 2001;33:963-971.
10. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-634.
11. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
12. Lok ASF, Chung H-T, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-1838.
13. Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001;34:1225-1241.
14. Hsu Y-S, Chien R-N, Yeh C-T, Sheen I-S, Chiou H-Y, Chu C-M, Liaw Y-F. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. HEPATOLOGY 2002;35:1522-1527.
15. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-748.
16. Fattovich G, Rugge M, Brollow L, Pontisso P, Noventa F, Guido M, Albetti A, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. HEPATOLOGY 1986;6:167-172.
17. Yang H-I, Lu S-N, Liaw Y-F, You S-L, Sun C-A, Wang L-Y, Hsiao CK, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.
18. Guan R, Liaw YF, Leung NWY, Lim SG, Nicholls GJ, Dent JC. Durable HBeAg response in Chinese patients treated with lamivudine [Abstract]. J Gatroenterol Hepatol 2000;15(Suppl):l106.
19. Leung NW, Liaw Y-F, Chang T-T, Guan R, Lee C-M, Ng K-Y, Lim S-G, et al. Durable HBeAg response in Chinese patients treated with lamivudine. HEPATOLOGY 2001;34:348A.
20. Leung NWY, Lai C-L, Chang T-T, Guan R, Lee C-M, Ng K-Y, Lim S-G, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2001;33:1527-1532.
21. Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. HEPATOLOGY 2000;32:803-806.
22. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-212.